Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment

Structure Therapeutics Inc., a clinical-stage biopharmaceutical company focusing on developing innovative oral small molecule therapies, recently announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, to address obesity. This selection was disclosed through a press release issued by the company on December 17, 2024.

ACCG-2671, designed as an oral small molecule Dual Amylin and Calcitonin Receptor Agonist (DACRA), has shown promising outcomes in preclinical studies. It displayed potent target engagement, significant weight loss capabilities, a favorable safety profile, and pharmacokinetic properties that support once-daily dosing in humans. These positive results have paved the way for the molecule’s progression into Phase 1 clinical development, with expected initiation by the end of 2025.

Raymond Stevens, Ph.D., the Founder and Chief Executive Officer of Structure Therapeutics, expressed confidence in the potential of amylin-based therapies in treating obesity. He highlighted the efficacy of ACCG-2671, stating that as an oral small molecule, it could serve as a fundamental treatment option to enhance scalability and patient access to weight loss medications.

In preclinical evaluations, ACCG-2671 demonstrated robust in vitro activities towards the key amylin receptor and the calcitonin receptor. The molecule exhibited promising in vivo efficacy, along with a safety and pharmacokinetic profile conducive to daily oral dosing in humans, emphasizing its differentiation as an oral obesity treatment.

Xichen Lin, Ph.D., the Chief Scientific Officer of Structure Therapeutics, emphasized the significant potential of ACCG-2671 as an oral therapy for obesity and related conditions, citing its efficacy and oral small molecule profile reminiscent of cagrilintide.

Structure Therapeutics has leveraged its GPCR structure-based drug discovery platform to advance ACCG-2671 as the lead amylin receptor agonist, with ongoing efforts to develop a series of amylin-based drug candidates. The company’s commitment to innovation in this domain underscores its leadership in the metabolic disease treatment space.

Investors and interested parties can access additional information regarding Structure Therapeutics and its developments through the company’s website or the press release. The announcement marks a significant step in the company’s mission to address unmet medical needs in chronic metabolic and cardiopulmonary conditions with innovative treatment options.ENDOFARTICLE

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Structure Therapeutics’s 8K filing here.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.